Analyze correlation of inflammatory chemokine CXCL8 and lymphoid axillary lymph node metastasis in breast cancer
Sažetak
Background: In this study, we analyzed the relationship between serumchemokine CXC ligand 8 (CXCL8) and breast cancer (BC) and the predictive effect on axillary lymph node metastasis.
Methods: 121 BC patients and 104 healthy controls were included, and serum CXCL8 was detected by ELISA to compare the differences in the levels of CXCL8 and tumor markers in the two study groups. Pathological examinations revealed that 36 of the patients had axillary lymph node metastasis. To further evaluate the diagnostic value, the ROC curve was employed to analyze the ability of CXCL8, tumor marker and combined color Doppler ultrasound blood flow richness grade (Adler grade) to assess axillary lymph node metastasis in BC patients.
Results: Serum CXCL8 CEA, CA153, and CA27.29 were higher in BC patients than in controls (P < 0.05). Patients with lymph node metastasis had higher levels of CXCL8 CEA, CA153, and CA27.29 (P < 0.05). The AUC of CXCL8+tumor markers+Adler grade for the diagnosis of lymph node metastasis was 0.903 (95% CI: 0.850-0.957), with a sensitivity of 86.11% and a specificity of 82.35% (P < 0.001).
Conclusion: High expression of CXCL8 is closely associated with BC lymph node metastasis.
Sva prava zadržana (c) 2025 Ceng Li, Jinxiang Hou
Ovaj rad je pod Creative Commons Autorstvo 4.0 međunarodnom licencom.
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.